Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer.

Research output: Contribution to journalArticle

Abstract

Breast cancer (BC) is one of the leading causes of death among women worldwide. Immunostimulatory treatment has increasingly been used as adjuvant therapy in the last few years, in patients with melanoma and other cancer forms, often with an induction of autoimmunity as a consequence of a successful treatment. We aimed at investigating if coexisting autoimmune diseases (AD) or hypersensitivities (HS) similarly to the side effects of immunostimulatory treatment resulted in a better overall survival, compared to patients without these disorders.

Details

Authors
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Article number357
JournalSpringerPlus
Volume2
Publication statusPublished - 2013
Publication categoryResearch
Peer-reviewedYes

Total downloads

No data available